| Ytd | 71.72% | |
| 1y | 28.79% |
| Open | 2.02 | Prev Close | 1.36 | Low | 1.53 | High | 2.20 | Mkt Cap | 11.27M |
| Vol | 0.00 | Avg Vol | 10.56M | EPS | -0.80 | P/E | -1.06 | Forward P/E | -1.15 |
| Beta | 0.57 | Short Ratio | 0.25 | Inst. Own | 5.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 0.80 | 200-d Avg | 1.11 | 1yr Est | 4.50 |
HOTH News
Hoth Therapeutics stock surged after announcing its Rocket One rebrand and new AI chip technology fo
Company Adopts Space-Focused Identity, New Ticker "RKTO," and Exclusive License of AI Chip Architect
Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce
Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Spi
Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningf
Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism)
Bloom Energy (BE) rose in pre-market trading as it announces expanded partnership with Oracle (ORCL)
Statistically Significant Reduction in Srebf1 (Fat Production) and Increased Pparα (Fat Metabolism)
NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage bio
NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage bio
Over 65% of Patients Reported Reduced Pain and Itching; Zero Disruptions to EGFR Cancer Therapy with
Technology Selectively Shuts Down Cancer Reproducing Cells Patent Covers Splice-Switching Oligonucle
NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage bi
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with se
AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers NEW YORK,
CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patie
In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Adminis
Hoth Therapeutics Inc. (NASDAQ: HOTH) on Tuesday revealed preclinical data from its study on glial c
NEW YORK, Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biop
Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reachin
On Thursday, 369 companies hit new 52-week lows.
On Monday, 369 companies set new 52-week lows.
Monday saw 196 companies set new 52-week lows.
On Tuesday, 120 companies set new 52-week lows.
During Wednesday's trading, 517 companies set new 52-week lows.
During Monday's session, 402 companies made new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.